VKTX Stock Eyes Best Week In 2 Years: Retail Bulls Bet Q3 Obesity Data Could Put Novo, Big Pharma In Buyout Play
Viking launched a Phase 1 trial for VK3019, a new weight-loss candidate. The move has revived buyout speculation,…
LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call
Truist assumed coverage on VKTX with a ‘Buy’ rating and an $83 price target, implying an upside of…